These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 27941374)
1. Delayed Gastric Emptying in Advanced Parkinson Disease: Correlation With Therapeutic Doses. Bestetti A; Capozza A; Lacerenza M; Manfredi L; Mancini F Clin Nucl Med; 2017 Feb; 42(2):83-87. PubMed ID: 27941374 [TBL] [Abstract][Full Text] [Related]
2. Gastric emptying time and gastric motility in patients with Parkinson's disease. Hardoff R; Sula M; Tamir A; Soil A; Front A; Badarna S; Honigman S; Giladi N Mov Disord; 2001 Nov; 16(6):1041-7. PubMed ID: 11748735 [TBL] [Abstract][Full Text] [Related]
3. Is there a difference in gastric emptying between Parkinson's disease patients under long-term L-dopa therapy with and without motor fluctuations? An analysis using the 13C-acetate breath test. Tanaka Y; Kato T; Nishida H; Araki H; Murase M; Nagaki M; Moriwaki H; Inuzuka T J Neurol; 2009 Dec; 256(12):1972-6. PubMed ID: 19575260 [TBL] [Abstract][Full Text] [Related]
4. [Gastrointestinal dysfunction has important implications for plasma L-dopa concentrations in Parkinson's disease]. Doi H; Sakakibara R; Kishi M; Tsuyuzaki Y; Tateno F; Hirai S Rinsho Shinkeigaku; 2013; 53(11):1382-5. PubMed ID: 24291998 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409 [TBL] [Abstract][Full Text] [Related]
6. Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal. Epprecht L; Schreglmann SR; Goetze O; Woitalla D; Baumann CR; Waldvogel D J Neurol; 2015 Aug; 262(8):1946-53. PubMed ID: 26048686 [TBL] [Abstract][Full Text] [Related]
7. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993 [TBL] [Abstract][Full Text] [Related]
8. Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. Doi H; Sakakibara R; Sato M; Masaka T; Kishi M; Tateno A; Tateno F; Tsuyusaki Y; Takahashi O J Neurol Sci; 2012 Aug; 319(1-2):86-8. PubMed ID: 22632782 [TBL] [Abstract][Full Text] [Related]
9. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Djaldetti R; Baron J; Ziv I; Melamed E Neurology; 1996 Apr; 46(4):1051-4. PubMed ID: 8780089 [TBL] [Abstract][Full Text] [Related]
10. Gastroparesis and Parkinson's disease: a systematic review. Heetun ZS; Quigley EM Parkinsonism Relat Disord; 2012 Jun; 18(5):433-40. PubMed ID: 22209346 [TBL] [Abstract][Full Text] [Related]
11. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). Stocchi F; Marconi S Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107 [TBL] [Abstract][Full Text] [Related]
12. Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Nyholm D; Aquilonius SM Clin Neuropharmacol; 2004; 27(5):245-56. PubMed ID: 15602106 [TBL] [Abstract][Full Text] [Related]
13. When should levodopa therapy be initiated in patients with Parkinson's disease? Halkias IA; Haq I; Huang Z; Fernandez HH Drugs Aging; 2007; 24(4):261-73. PubMed ID: 17432922 [TBL] [Abstract][Full Text] [Related]
14. Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study. Destée A; Rérat K; Bourdeix I Eur Neurol; 2009; 61(2):69-75. PubMed ID: 19039224 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. Müller T Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910 [TBL] [Abstract][Full Text] [Related]
16. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
17. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease. Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905 [TBL] [Abstract][Full Text] [Related]
20. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide. Kurth MC Drugs Aging; 1997 May; 10(5):332-40. PubMed ID: 9143854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]